MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Up 0.7% – Time to Buy?

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) shares shot up 0.7% during trading on Wednesday . The company traded as high as $1.48 and last traded at $1.39. Approximately 648,116 shares changed hands during mid-day trading, a decline of 37% from the average session volume of 1,028,490 shares. The stock had previously closed at $1.38.

MAIA Biotechnology Stock Up 0.7%

The firm has a 50-day moving average of $1.33 and a two-hundred day moving average of $1.56. The company has a market capitalization of $84.51 million, a PE ratio of -2.07 and a beta of 0.23.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. On average, equities research analysts expect that MAIA Biotechnology, Inc. will post -0.52 EPS for the current year.

Insider Transactions at MAIA Biotechnology

In related news, CEO Vlad Vitoc acquired 72,700 shares of MAIA Biotechnology stock in a transaction that occurred on Monday, June 1st. The shares were purchased at an average cost of $1.39 per share, for a total transaction of $101,053.00. Following the acquisition, the chief executive officer owned 976,121 shares in the company, valued at approximately $1,356,808.19. This represents a 8.05% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Stan Smith acquired 75,000 shares of MAIA Biotechnology stock in a transaction that occurred on Monday, June 1st. The stock was bought at an average price of $1.34 per share, for a total transaction of $100,500.00. Following the completion of the acquisition, the director owned 1,519,178 shares in the company, valued at $2,035,698.52. This trade represents a 5.19% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 149,700 shares of company stock valued at $204,233 over the last three months. Corporate insiders own 19.81% of the company’s stock.

Institutional Investors Weigh In On MAIA Biotechnology

A number of institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after purchasing an additional 7,746 shares during the period. Centric Wealth Management raised its position in MAIA Biotechnology by 2.0% in the fourth quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock valued at $897,000 after purchasing an additional 11,500 shares during the period. Marshall Wace LLP purchased a new stake in MAIA Biotechnology in the second quarter valued at approximately $29,000. Ritholtz Wealth Management acquired a new position in MAIA Biotechnology during the fourth quarter worth $35,000. Finally, Jane Street Group LLC acquired a new position in MAIA Biotechnology during the second quarter worth $52,000. 5.65% of the stock is currently owned by institutional investors and hedge funds.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.